Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese

被引:1
|
作者
Shang, Guoguo [1 ,2 ,3 ]
Jin, Yan [1 ,2 ]
Zheng, Qiang [1 ,2 ]
Shen, Xuxia [1 ,2 ]
Yang, Mu [4 ]
Li, Yuan [1 ,2 ]
Zhang, Lanjing [5 ,6 ,7 ,8 ]
机构
[1] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Dept Pathol, Zhongshan Hosp, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Pathol, Sch Med, Shanghai, Peoples R China
[5] Rutgers State Univ, Dept Biol Sci, Newark, NJ USA
[6] Med Ctr Princeton, Dept Pathol, Plainsboro, NJ USA
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[8] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Chem Biol, Piscataway, NJ USA
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2019年 / 9卷 / 06期
基金
中国国家自然科学基金;
关键词
Lung cancer; pathology; survival; oncogenic driver; adenocarcinoma; INVASIVE MUCINOUS ADENOCARCINOMA; CLINICOPATHOLOGICAL CHARACTERISTICS; INTERNATIONAL ASSOCIATION; FUSIONS DEFINE; RET FUSIONS; ALK; MUTATIONS; PROGNOSIS; SUBTYPES; SMOKERS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known about association of mucin abundancy with oncogenic-driver alterations, immunohistochemical and clinicopathologic features in lung adenocarcinomas among Chinese. We here retrospectively examined the clinicopathologic and molecular characteristics of pulmonary mucin-producing adenocarcinoma (PMPA) and previously-reported non-mucinous lung adenocarcinomas collected at our institution. Among the 897 non-mucinous adenocarcinomas, 61 PMPA with <= 90% mucin and 39 PMPA with >90% mucin, ALK rearrangements were found in 47 (5.2%) non-mucinous adenocarcinomas, 9 (14.8%) PMPA with 5.90% mucin and 12 (30.8%) PMPA with >90% mucin, respectively, with an ordinal association (coefficient, 95% CI=0.11, 0.06 to 0.17). Similarly, KRAS mutations was found in 53 (5.9%) non-mucinous adenocarcinomas, 7 (11.5%) PMPA with <= 90% mucin and 14 (35.9%) PMPA with >90% mucin (coefficient, 95% CI=0.11, 0.05 to 0.16). However, mucinous abundancy was inversely, ordinally linked to the EGFR mutations (coefficient, 95% C1=-0.28, -0.33 to -0.22). Mucin abundancy seemed not associated with the alterations of HER2, BRAF, ROS1, MET and RET. We divided PMPA with >90% mucin into three histologic types, namely columnar mucinous cell with basal nuclei (type I, n=11), cuboidal cell with goblet cell feature (type II, n=16) and mucinous cribriform pattern (type III, n=12). These histologic subtypes were associated with alterations of ALK, KRAS and MET, and the immunohistochemical reactivity of MUC1, MUC2, MUC5ac, MUC6, TTF-1 and CK20, including high positive rate of MUC6 (90.9%) and CK20 (36.4%) in type I, MUC2 (50%) in type II and MUC1 (100%) in type III. In summary, mucin abundancy is associated with immunohistochemical and oncogenic-driver profiles of lung adenocarcinomas among Chinese.
引用
收藏
页码:1212 / 1223
页数:12
相关论文
共 50 条
  • [41] Unique profiles of targetable genomic alterations and prognosis in young Chinese patients with lung adenocarcinoma
    Chen, Lijuan
    Hu, Xiufeng
    Wu, Huijuan
    Liu, Jie
    Mu, Xiaoqian
    Wu, Hongbo
    Zhao, Yanqiu
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [42] Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations
    Harris, Jeremy P.
    Fujimoto, Dylann K.
    Nagasaka, Misako
    Ku, Eric
    Harada, Garrett
    Keshava, Hari
    Mahtabifard, Ali
    Longoria, Javier
    Patel, Niral
    Seyedin, Steven
    Simon, Aaron
    Chen, Allen
    CLINICAL LUNG CANCER, 2022, 23 (04) : 333 - 344
  • [43] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
    Beninato, T.
    Brambilla, M.
    Pircher, C. C.
    Mazzeo, L.
    Rametta, A.
    Manglaviti, S.
    De Toma, A.
    Galli, G.
    Prelaj, A.
    Ferrara, R.
    Proto, C.
    Lo Russo, G.
    Ganzinelli, M.
    Di Mauro, R.
    Di Nucci, A.
    Garassino, M. C.
    Marchetti, P.
    De Braud, F. G. M.
    Occhipinti, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1046 - S1046
  • [44] Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma
    Dong, Yu
    Li, Ying
    Jin, Bo
    Zhang, Jie
    Shao, Jinchen
    Peng, Hong
    Tu, Shichun
    Han, Baohui
    ONCOTARGET, 2017, 8 (47) : 82244 - 82255
  • [45] PROFILING OF ACTIONABLE ALTERATIONS IN LUNG ADENOCARCINOMA
    Prabhash, Kumar
    Chandrani, Pratik
    Aich, Jyotirmoi
    Upadhyay, Pawan
    Chougule, Anuradha
    Noronha, Vanita
    Joshi, Amit
    Desai, Saral
    Jambekar, Nirmala
    Thavamani, Abhishek
    Jose, Tony
    Chandna, Puneet
    Dutt, Amit
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1261 - S1261
  • [46] Discovery of actionable alterations in lung adenocarcinoma
    Chandrani, P.
    Prasad, R.
    Chougule, A.
    Sethunath, V.
    Aich, J.
    Dhamne, H.
    Upadhyay, P.
    Iyer, D. N.
    Thavamani, A.
    Mohanty, B.
    Thorat, R.
    Chaudhari, P.
    Sindhi, R.
    Chandna, P.
    Prabhash, K.
    Dutt, A.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : S55 - S56
  • [47] Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma
    Tischler, V.
    Ihle, M. A.
    Stenzinger, A.
    Weichert, W.
    Jochum, W.
    Buettner, R.
    Wolf, J.
    Peifer, M.
    Thomas, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S12 - S12
  • [48] Oncogenic RIT1 mutations in lung adenocarcinoma
    A H Berger
    M Imielinski
    F Duke
    J Wala
    N Kaplan
    G-X Shi
    D A Andres
    M Meyerson
    Oncogene, 2014, 33 : 4418 - 4423
  • [49] BARD1, AN ONCOGENIC DRIVER AND BIOMARKER OF LUNG CANCER
    Pilyugin, M.
    Andre, P.
    Laurent, G.
    Irminger-Finger, I.
    RESPIROLOGY, 2014, 19 : 17 - 17
  • [50] Oncogenic SOS1 Mutations in Lung Adenocarcinoma
    Cai, D.
    Choi, P.
    Meyerson, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1825 - S1825